Renal cell carcinoma with multiple bone metastases effectively treated by a combination of tyrosine kinase inhibitor, robot‐assisted partial nephrectomy, and metastasectomy

Key Clinical Message Maintaining a disease‐free status for a long time in cases of renal cell carcinoma with multiple bone metastases and repeated recurrences is challenging. What matters most in the multidisciplinary approach is the treatment strategy. Although this is a case where multidisciplinar...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical Case Reports 2024-03, Vol.12 (3), p.e8482-n/a
Hauptverfasser: Sawada, Atsuro, Takeda, Masashi, Goto, Takayuki, Akamatsu, Shusuke, Kobayashi, Takashi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Key Clinical Message Maintaining a disease‐free status for a long time in cases of renal cell carcinoma with multiple bone metastases and repeated recurrences is challenging. What matters most in the multidisciplinary approach is the treatment strategy. Although this is a case where multidisciplinary treatment resulted in long‐term CR during the TKI era, the treatment strategy is still relevant now that treatment options have increased. Recent advances in medications, such as immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs), have improved metastatic renal cell carcinoma (mRCC) outcomes. We report a case of mRCC with bone metastasis that was successfully treated using a multidisciplinary approach. Here, we present a case of a 56‐year‐old man with left renal cancer and large and painful bone metastases at the 11th thoracic vertebrae (Th11). Therefore, a metastasectomy of Th11 was performed. Systemic treatment with TKI, robot‐assisted partial nephrectomy, and metastasectomy were then administered. No recurrence was observed in >2 years. Long‐term disease‐free survival with the TKI‐era multidisciplinary approach in a patient with mRCC remains significant when considering treatment sequences, especially now that drug treatment options—including ICIs—have increased. Treatment strategy and indication and timing of resection of the primary lesion and metastasectomy should be carefully considered in each case.
ISSN:2050-0904
2050-0904
DOI:10.1002/ccr3.8482